ELVN - CIK 0001672619
Enliven Therapeutics, Inc. (ELVN) reported net income of -$103.70M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$103.70M | -16.5% |
| FY 2024 | -$89.00M | -24.3% |
| FY 2023 | -$71.58M | -90.1% |
| FY 2022 | -$37.66M | -52.2% |
| FY 2021 | -$24.74M | +40.2% |
| FY 2020 | -$41.36M | -76.3% |
| FY 2019 | -$23.46M | - |
Enliven Therapeutics, Inc. (ELVN) reported net income of -$103.70M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Enliven Therapeutics, Inc.'s net income declined from -$23.46M to -$103.70M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.